ConductScience.org, home

Paper40705396

Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial.

Ngoi NYL and 18 others. Clin Cancer Res, 2025. Cited by 9 papers, by iCite.

Cite this record

ConductScience Library. Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial. Papers, record 40705396. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40705396

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial.
PubMed
Journal
Clin Cancer Res
PubMed
Year
2025
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, Multicenter Study
PubMed
Citations, by iCite
9
iCite
Relative citation ratio, by iCite
2.15, provisional
iCite
Revised in PubMed
2026-09-16
PubMed

Authors19

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Ovarian NeoplasmsMajor topic
Adenocarcinoma, Clear CellMajor topic
Antibodies, MonoclonalMajor topic
Neoplasm Recurrence, LocalMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Humans
Female
Middle Aged
Aged
Adult
Aged, 80 and over
Progression-Free Survival

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
AstraZeneca (AstraZeneca PLC)PubMed
NMRC/MOHIAFCat1/0061/2016National Medical Research Council (NMRC)PubMed
CSASI21jun-0003Indian Institute of Science Education and Research Mohali (IISER)PubMed
Pangestu Family Foundation Gynaecological Cancer Research FundPubMed

Source PubMed

Download CSV of grants

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134322886A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinoma.J Pathol2021https://conductscience.org/library/papers/34322886PubMed
236244829A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.Gynecol Oncol2022https://conductscience.org/library/papers/36244829PubMed
339710508Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80).J Gynecol Oncol2025https://conductscience.org/library/papers/39710508PubMed
435264433PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment.J Immunother Cancer2022https://conductscience.org/library/papers/35264433PubMed
536095166The Tumor Microenvironment of Clear-Cell Ovarian Cancer.Cancer Immunol Res2022https://conductscience.org/library/papers/36095166PubMed
610861437Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.Cancer2000https://conductscience.org/library/papers/10861437PubMed
730824583Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.Clin Cancer Res2019https://conductscience.org/library/papers/30824583PubMed
821343371IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.Clin Cancer Res2011https://conductscience.org/library/papers/21343371PubMed
929739622Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).Gynecol Oncol2018https://conductscience.org/library/papers/29739622PubMed
1021640372Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis.Gynecol Oncol2011https://conductscience.org/library/papers/21640372PubMed
1128344892Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression.Oncoimmunology2017https://conductscience.org/library/papers/28344892PubMed
1228266140Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma.Cancer Sci2017https://conductscience.org/library/papers/28266140PubMed
1335816189Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes.Clin Cancer Res2022https://conductscience.org/library/papers/35816189PubMed
1426813747Mismatch Repair Protein Expression in Clear Cell Carcinoma of the Ovary: Incidence and Morphologic Associations in 109 Cases.Am J Surg Pathol2016https://conductscience.org/library/papers/26813747PubMed
1531046082Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.Ann Oncol2019https://conductscience.org/library/papers/31046082PubMed
1634247767Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes.Gynecol Oncol2021https://conductscience.org/library/papers/34247767PubMed
1734064019Estimating Relative Risk When Observing Zero Events-Frequentist Inference and Bayesian Credibility Intervals.Int J Environ Res Public Health2021https://conductscience.org/library/papers/34064019PubMed
1818081792Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.Int J Gynecol Cancer2008https://conductscience.org/library/papers/18081792PubMed
1932581055IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.J Immunother Cancer2020https://conductscience.org/library/papers/32581055PubMed
2031924330High homogeneity of MMR deficiency in ovarian cancer.Gynecol Oncol2020https://conductscience.org/library/papers/31924330PubMed

See all 28 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.

PMIDTitleJournalYearIn PapersSource
42984928Immunotherapy in Advanced Epithelial Ovarian Cancer: Successes and Frustrations.Oncol Res2026https://conductscience.org/library/papers/42984928PubMed
42891872Histotype and molecular subtype integration in epithelial ovarian cancer: implications for targeted treatment.Cancer Metastasis Rev2026https://conductscience.org/library/papers/42891872PubMed
41888752Twenty-four months progression-free survival (ongoing) for treatment of recurrent ovarian clear cell carcinoma with surufatinib in combination with toripalimab: a case report.BMC Womens Health2026https://conductscience.org/library/papers/41888752PubMed
41697393AI-based quantification of tumor-infiltrating lymphocytes with integrative transcriptomics in ovarian clear cell carcinoma: JGOG3025-TR1/A1 study.Cancer Immunol Immunother2026https://conductscience.org/library/papers/41697393PubMed
41020848Tumor Immune Microenvironment and Checkpoint Inhibition in Clear Cell Ovarian Carcinoma: Bridging Tumor Biology and Clinical Application in Immunotherapy.Curr Issues Mol Biol2025https://conductscience.org/library/papers/41020848PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
PIK3CA5290PubTator's text mininghttps://conductscience.org/library/genes/5290NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40705396

GET https://conductscience.org/api/papers/v1/40705396/references?page=2